

ASX ANNOUNCEMENT

26 FEBRUARY 2024



Germany legalises *cannabis*



Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") is pleased to announce that in an historic move, the German Bundestag voted on Friday to legalise cannabis by removing it from the Narcotics List from 1 April 2024. This represents the most significant legislative change in global cannabis markets since Canada legalised cannabis in 2018.

Germany is currently the largest medicinal cannabis market in Europe. The change will make it the largest federally legal cannabis market globally, and is anticipated to result in an increase in the number of patients and consumers by multiples while catalysing similar changes across Europe.

The change allows for the establishment of not-for-profit cannabis clubs, limited home cultivation and possession of personal use quantities. Critically, the decision removes cannabis from the Narcotics List, meaning the existing medical access pathway will be substantially improved through the removal of prescribed conditions, narcotic reporting, and pharmacy stockholding limitations; and the easing of the rules around telehealth services, e-scripts, and direct delivery to patients.

The new laws present LGP with a unique opportunity given its well-established partnerships with multiple German distributors, large bank of cannabis genetics, and ownership of the largest and most advanced EU GMP recognised medicinal cannabis facility in Europe strategically located just two hours from the German border. Ongoing EU GMP standards for medicinal cannabis will also continue to constrain North American non-GMP supplier participation in the market. For more information see LGP investor presentation dated 8 February 2024: [Investor-Webinar-December-Quarterly-Results-Presentation.pdf \(investlittlegreenpharma.com\)](#).

ENDS

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomass per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp